BRAVELLE

This brand name is authorized in Ecuador, Estonia, Lithuania, Poland, Singapore, South Africa

Active ingredients

The drug BRAVELLE contains one active pharmaceutical ingredient (API):

1 Urofollitropin UNII W9BB98U6HP - UROFOLLITROPIN

Urofollitropin contains a highly purified preparation of urinary FSH extracted from the urine of postmenopausal women. FSH stimulates ovarian follicular growth and development as well as gonadal steroid production in women who do not have primary ovarian failure. Read about Urofollitropin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRAVELLE Powder and solvent for solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03GA04	Urofollitropin	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 29113-12-09
Country: EE	Ravimiamet	Identifier(s): 1307001, 1307012, 1402782
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1026274, 1026596
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100193237
Country: SG	Health Sciences Authority	Identifier(s): 14420P
Country: ZA	Health Products Regulatory Authority	Identifier(s): 44/21.10/0763